## SÃ, ren Buus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611288/publications.pdf Version: 2024-02-01



SÃ DEN RILLS

#	Article	IF	CITATIONS
1	Minimal Information about MHC Multimers (MIAMM). Journal of Immunology, 2022, 208, 531-537.	0.8	Ο
2	Defective Proinsulin Handling Modulates the MHC I Bound Peptidome and Activates the Inflammasome in β-Cells. Biomedicines, 2022, 10, 814.	3.2	3
3	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nature Communications, 2021, 12, 324.	12.8	79
4	Integral Use of Immunopeptidomics and Immunoinformatics for the Characterization of Antigen Presentation and Rational Identification of BoLA-DR–Presented Peptides and Epitopes. Journal of Immunology, 2021, 206, 2489-2497.	0.8	15
5	Normal T and B Cell Responses Against SARS-CoV-2 in a Family With a Non-Functional Vitamin D Receptor: A Case Report. Frontiers in Immunology, 2021, 12, 758154.	4.8	7
6	CD8+ T cells variably recognize native versus citrullinated GRP78 epitopes in type 1 diabetes. Diabetes, 2021, 70, db210259.	0.6	11
7	Efficient Control of Zika Virus Infection Induced by a Non-Replicating Adenovector Encoding Zika Virus NS1/NS2 Antigens Fused to the MHC Class II-Associated Invariant Chain. Viruses, 2021, 13, 2215.	3.3	Ο
8	Unbiased Characterization of Peptide-HLA Class II Interactions Based on Large-Scale Peptide Microarrays; Assessment of the Impact on HLA Class II Ligand and Epitope Prediction. Frontiers in Immunology, 2020, 11, 1705.	4.8	5
9	A Systematic, Unbiased Mapping of CD8+ and CD4+ T Cell Epitopes in Yellow Fever Vaccinees. Frontiers in Immunology, 2020, 11, 1836.	4.8	13
10	Effector CD8 T Cell-Dependent Zika Virus Control in the CNS: A Matter of Time and Numbers. Frontiers in Immunology, 2020, 11, 1977.	4.8	10
11	Peptides Derived From Insulin Granule Proteins Are Targeted by CD8+ T Cells Across MHC Class I Restrictions in Humans and NOD Mice. Diabetes, 2020, 69, 2678-2690.	0.6	34
12	Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial. Trials, 2020, 21, 1015.	1.6	7
13	Immunoinformatics: Predicting Peptide–MHC Binding. Annual Review of Biomedical Data Science, 2020, 3, 191-215.	6.5	51
14	HLA Class II Specificity Assessed by High-Density Peptide Microarray Interactions. Journal of Immunology, 2020, 205, 290-299.	0.8	13
15	T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species. Journal of Virology, 2020, 94, .	3.4	49
16	NNAlign_MA; MHC Peptidome Deconvolution for Accurate MHC Binding Motif Characterization and Improved T-cell Epitope Predictions. Molecular and Cellular Proteomics, 2019, 18, 2459-2477.	3.8	87
17	Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Molecular Therapy - Methods and Clinical Development, 2019, 12, 32-46.	4.1	74
18	Islet-reactive CD8 <sup>+</sup> T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Science Immunology, 2018, 3, .	11.9	171

#	Article	IF	CITATIONS
19	Improved methods for predicting peptide binding affinity to <scp>MHC</scp> class <scp>II</scp> molecules. Immunology, 2018, 154, 394-406.	4.4	629
20	Differential Immunodominance Hierarchy of CD8 <sup>+</sup> T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	14
21	Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes. Oncotarget, 2018, 9, 4737-4757.	1.8	13
22	Footprints of antigen processing boost MHC class II natural ligand predictions. Genome Medicine, 2018, 10, 84.	8.2	86
23	Major TCR Repertoire Perturbation by Immunodominant HLA-B*44:03-Restricted CMV-Specific T Cells. Frontiers in Immunology, 2018, 9, 2539.	4.8	25
24	Conventional and Neo-antigenic Peptides Presented by β Cells Are Targeted by Circulating NaÃ⁻ve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. Cell Metabolism, 2018, 28, 946-960.e6.	16.2	177
25	A New In Vivo Model to Study Protective Immunity to Zika Virus Infection in Mice With Intact Type I Interferon Signaling. Frontiers in Immunology, 2018, 9, 593.	4.8	38
26	Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Science Translational Medicine, 2017, 9, .	12.4	57
27	HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer <sup>+</sup> Gag-Specific CD4 <sup>+</sup> T Cells in Chronic Clade C HIV-1 Infection. Journal of Virology, 2017, 91, .	3.4	24
28	Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. Scientific Reports, 2017, 7, 662.	3.3	35
29	Prediction and in vitro verification of potential CTL epitopes conserved among PRRSV-2 strains. Immunogenetics, 2017, 69, 689-702.	2.4	10
30	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. Journal of Virology, 2017, 91, .	3.4	14
31	Low antigen dose formulated in CAF09 adjuvant Favours a cytotoxic T-cell response following intraperitoneal immunization in GA¶ttingen minipigs. Vaccine, 2017, 35, 5629-5636.	3.8	19
32	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Scientific Reports, 2017, 7, 8653.	3.3	41
33	Structural Elements Recognized by Abacavir-Induced T Cells. International Journal of Molecular Sciences, 2017, 18, 1464.	4.1	21
34	Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities. PLoS ONE, 2017, 12, e0184496.	2.5	2
35	HIV-1 adaptation to NK cell-mediated immune pressure. PLoS Pathogens, 2017, 13, e1006361.	4.7	11
36	ArrayPitope: Automated Analysis of Amino Acid Substitutions for Peptide Microarray-Based Antibody Epitope Mapping. PLoS ONE, 2017, 12, e0168453.	2.5	11

#	Article	IF	CITATIONS
37	Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations. PLoS ONE, 2017, 12, e0189612.	2.5	24
38	Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0004464.	3.0	20
39	Pan-Specific Prediction of Peptide–MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity. Journal of Immunology, 2016, 197, 1517-1524.	0.8	198
40	Expanding specificity of class I restricted CD8+ T cells for viral epitopes following multiple inoculations of swine with a human adenovirus vectored foot-and-mouth disease virus (FMDV) vaccine. Veterinary Immunology and Immunopathology, 2016, 181, 59-67.	1.2	8
41	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. Journal of Immunology, 2016, 196, 2205-2218.	0.8	55
42	A combined prediction strategy increases identification of peptides bound with high affinity and stability to porcine MHC class I molecules SLA-1*04:01, SLA-2*04:01, and SLA-3*04:01. Immunogenetics, 2016, 68, 157-165.	2.4	14
43	Immunogenicity of HLA Class I and II Double Restricted Influenza A-Derived Peptides. PLoS ONE, 2016, 11, e0145629.	2.5	11
44	Disease progression despite protective HLA expression in an HIV-infected transmission pair. Retrovirology, 2015, 12, 55.	2.0	11
45	Establishing the pig as a large animal model for vaccine development against human cancer. Frontiers in Genetics, 2015, 6, 286.	2.3	24
46	Abacavir-Reactive Memory T Cells Are Present in Drug NaÃ⁻ve Individuals. PLoS ONE, 2015, 10, e0117160.	2.5	73
47	Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. PLoS ONE, 2015, 10, e0124878.	2.5	11
48	Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. Diabetes, 2015, 64, 3532-3542.	0.6	24
49	CD8+ T Cells Complement Antibodies in Protecting against Yellow Fever Virus. Journal of Immunology, 2015, 194, 1141-1153.	0.8	70
50	Different binding motifs of the celiac disease-associated HLA molecules DQ2.5, DQ2.2, and DQ7.5 revealed by relative quantitative proteomics of endogenous peptide repertoires. Immunogenetics, 2015, 67, 73-84.	2.4	94
51	A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape. Retrovirology, 2015, 12, 20.	2.0	35
52	CD8+ TCR Bias and Immunodominance in HIV-1 Infection. Journal of Immunology, 2015, 194, 5329-5345.	0.8	48
53	A modern approach for epitope prediction: identification of foot-and-mouth disease virus peptides binding bovine leukocyte antigen (BoLA) class I molecules. Immunogenetics, 2015, 67, 691-703.	2.4	16
54	Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics, 2015, 67, 641-650.	2.4	291

SÃ, ren Buus

#	Article	IF	CITATIONS
55	Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity, 2015, 43, 591-604.	14.3	234
56	HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma. British Journal of Cancer, 2015, 113, 952-962.	6.4	16
57	T Cell–Mediated Hypersensitivity Reactions to Drugs. Annual Review of Medicine, 2015, 66, 439-454.	12.2	109
58	Automated High-Throughput Mapping of Linear B-Cell Epitopes Using a Statistical Analysis of High-Density Peptide Microarray Data. Methods in Molecular Biology, 2015, 1348, 215-228.	0.9	2
59	Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding. ELife, 2015, 4, e05345.	6.0	107
60	Identification and HLA-Tetramer-Validation of Human CD4+ and CD8+ T Cell Responses against HCMV Proteins IE1 and IE2. PLoS ONE, 2014, 9, e94892.	2.5	22
61	Uncovering the Peptide-Binding Specificities of HLA-C: A General Strategy To Determine the Specificity of Any MHC Class I Molecule. Journal of Immunology, 2014, 193, 4790-4802.	0.8	85
62	Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load. Aids, 2014, 28, 2007-2021.	2.2	17
63	<scp>Net</scp> <scp>MHC</scp> <scp>stab</scp> – predicting stability of peptide– <scp>MHC</scp> â€ complexes; impacts for cytotoxic <scp>T</scp> lymphocyte epitope discovery. Immunology, 2014, 141, 18-26.	4.4	105
64	HIV Subtype Influences HLA-B*07:02-Associated HIV Disease Outcome. AIDS Research and Human Retroviruses, 2014, 30, 468-475.	1.1	19
65	Soluble Human Leukocyte Antigen-G in Seminal Plasma is Associated with HLA-G Genotype: Possible Implications for Fertility Success. American Journal of Reproductive Immunology, 2014, 72, 89-105.	1.2	34
66	Characterization of binding specificities of bovine leucocyte class I molecules: impacts for rational epitope discovery. Immunogenetics, 2014, 66, 705-718.	2.4	21
67	Dataset size and composition impact the reliability of performance benchmarks for peptide-MHC binding predictions. BMC Bioinformatics, 2014, 15, 241.	2.6	71
68	HLA class Iâ€drugâ€Tâ€cell receptor interactions in SJS/TEN. Clinical and Translational Allergy, 2014, 4, P2.	3.2	0
69	Use of "one-pot, mix-and-read―peptide-MHC class I tetramers and predictive algorithms to improve detection of cytotoxic T lymphocyte responses in cattle. Veterinary Research, 2014, 45, 50.	3.0	30
70	NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. Immunogenetics, 2013, 65, 711-724.	2.4	254
71	MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics, 2013, 65, 655-665.	2.4	116
72	Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Scientific Reports, 2013, 3, 1162.	3.3	23

SÃ, ren Buus

#	Article	IF	CITATIONS
73	Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1. Malaria Journal, 2013, 12, 376.	2.3	18
74	Peptide pool immunization and CD8+ T cell reactivity. Immunology Letters, 2013, 151, 48-53.	2.5	0
75	Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy. Immunopharmacology and Immunotoxicology, 2013, 35, 487-496.	2.4	5
76	Comparison of Vaccine-Induced Effector CD8 T Cell Responses Directed against Self- and Non–Self-Tumor Antigens: Implications for Cancer Immunotherapy. Journal of Immunology, 2013, 191, 3955-3967.	0.8	57
77	HLA-A*68. Aids, 2013, 27, 1717-1723.	2.2	7
78	HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 Monochain Transgenic/H-2 Class I Null Mice: Novel Versatile Preclinical Models of Human T Cell Responses. Journal of Immunology, 2013, 191, 583-593.	0.8	37
79	Tapasin Facilitation of Natural HLA-A and -B Allomorphs Is Strongly Influenced by Peptide Length, Depends on Stability, and Separates Closely Related Allomorphs. Journal of Immunology, 2013, 191, 3939-3947.	0.8	14
80	HLA-Specific Intracellular Epitope Processing Shapes an Immunodominance Pattern for HLA-B*57 That Is Distinct from HLA-B*58:01. Journal of Virology, 2013, 87, 10889-10894.	3.4	8
81	Identification and Mapping of Linear Antibody Epitopes in Human Serum Albumin Using High-Density Peptide Arrays. PLoS ONE, 2013, 8, e68902.	2.5	45
82	Nef-Specific CD8+ T Cell Responses Contribute to HIV-1 Immune Control. PLoS ONE, 2013, 8, e73117.	2.5	36
83	Discovering naturally processed antigenic determinants that confer protective T cell immunity. Journal of Clinical Investigation, 2013, 123, 1976-1987.	8.2	58
84	MHC Class II Tetramers Made from Isolated Recombinant α and β Chains Refolded with Affinity-Tagged Peptides. PLoS ONE, 2013, 8, e73648.	2.5	13
85	Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the United States of America, 2012, 109, 9959-9964.	7.1	354
86	HLA-B*57 Micropolymorphism Shapes HLA Allele-Specific Epitope Immunogenicity, Selection Pressure, and HIV Immune Control. Journal of Virology, 2012, 86, 919-929.	3.4	66
87	High-resolution Mapping of Linear Antibody Epitopes Using Ultrahigh-density Peptide Microarrays. Molecular and Cellular Proteomics, 2012, 11, 1790-1800.	3.8	166
88	Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes. Human Vaccines and Immunotherapeutics, 2012, 8, 987-1000.	3.3	13
89	HLA-B7–Restricted Islet Epitopes Are Differentially Recognized in Type 1 Diabetic Children and Adults and Form Weak Peptide-HLA Complexes. Diabetes, 2012, 61, 2546-2555.	0.6	19
90	HIV Control through a Single Nucleotide on the HLA-B Locus. Journal of Virology, 2012, 86, 11493-11500.	3.4	41

#	Article	IF	CITATIONS
91	Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. Journal of Virology, 2012, 86, 12643-12654.	3.4	49
92	Designing bovine T cell vaccines via reverse immunology. Ticks and Tick-borne Diseases, 2012, 3, 188-192.	2.7	32
93	Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine, 2012, 30, 7547-7560.	3.8	13
94	Identification of Conserved Subdominant HIV Type 1 CD8 <sup>+</sup> T Cell Epitopes Restricted Within Common HLA Supertypes for Therapeutic HIV Type 1 Vaccines. AIDS Research and Human Retroviruses, 2012, 28, 1434-1443.	1.1	10
95	Humoral and Cellular CMV Responses in Healthy Donors; Identification of a Frequent Population of CMV-Specific, CD4+ T Cells in Seronegative Donors. PLoS ONE, 2012, 7, e31420.	2.5	18
96	Peptideâ€ <scp>MHC</scp> class I stability is a better predictor than peptide affinity of <scp>CTL</scp> immunogenicity. European Journal of Immunology, 2012, 42, 1405-1416.	2.9	187
97	Cancer Associated Aberrant Protein O-Glycosylation Can Modify Antigen Processing and Immune Response. PLoS ONE, 2012, 7, e50139.	2.5	54
98	Genome-Based In Silico Identification of New <i>Mycobacterium tuberculosis</i> Antigens Activating Polyfunctional CD8+ T Cells in Human Tuberculosis. Journal of Immunology, 2011, 186, 1068-1080.	0.8	50
99	NNAlign: A Web-Based Prediction Method Allowing Non-Expert End-User Discovery of Sequence Motifs in Quantitative Peptide Data. PLoS ONE, 2011, 6, e26781.	2.5	60
100	Human Leukocyte Antigen (HLA) Class I Restricted Epitope Discovery in Yellow Fewer and Dengue Viruses: Importance of HLA Binding Strength. PLoS ONE, 2011, 6, e26494.	2.5	30
101	T Cells Recognizing a Peptide Contaminant Undetectable by Mass Spectrometry. PLoS ONE, 2011, 6, e28866.	2.5	5
102	Wildtype p53-specific Antibody and T-Cell Responses in Cancer Patients. Journal of Immunotherapy, 2011, 34, 629-640.	2.4	10
103	Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides. Immunology, 2011, 132, 482-491.	4.4	28
104	Real-time, high-throughput measurements of peptide–MHC-I dissociation using a scintillation proximity assay. Journal of Immunological Methods, 2011, 374, 5-12.	1.4	66
105	HLArestrictor—a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics, 2011, 63, 43-55.	2.4	63
106	Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities. Immunogenetics, 2011, 63, 821-834.	2.4	37
107	Tapasin Discriminates Peptide-Human Leukocyte Antigen-A*02:01 Complexes Formed with Natural Ligands. Journal of Biological Chemistry, 2011, 286, 20547-20557.	3.4	13
108	HLA-A*7401–Mediated Control of HIV Viremia Is Independent of Its Linkage Disequilibrium with HLA-B*5703. Journal of Immunology, 2011, 186, 5675-5686.	0.8	49

#	Article	IF	CITATIONS
109	Induction of Foot-and-Mouth Disease Virus-Specific Cytotoxic T Cell Killing by Vaccination. Vaccine Journal, 2011, 18, 280-288.	3.1	50
110	MHC Class II epitope predictive algorithms. Immunology, 2010, 130, 319-328.	4.4	198
111	Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology, 2010, 130, 309-318.	4.4	109
112	Identification of CD8+ T Cell Epitopes in the West Nile Virus Polyprotein by Reverse-Immunology Using NetCTL. PLoS ONE, 2010, 5, e12697.	2.5	41
113	Structural Properties of MHC Class II Ligands, Implications for the Prediction of MHC Class II Epitopes. PLoS ONE, 2010, 5, e15877.	2.5	19
114	Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8 + T Cells. Journal of Virology, 2010, 84, 10543-10557.	3.4	84
115	NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Research, 2010, 6, 9.	0.1	132
116	Degree of Predicted Minor Histocompatibility Antigen Mismatch Correlates with Poorer Clinical Outcomes in Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1370-1381.	2.0	11
117	HLA Class I Binding 9mer Peptides from Influenza A Virus Induce CD4+ T Cell Responses. PLoS ONE, 2010, 5, e10533.	2.5	24
118	Peptide Binding to HLA Class I Molecules: Homogenous, High-Throughput Screening, and Affinity Assays. Journal of Biomolecular Screening, 2009, 14, 173-180.	2.6	76
119	Elimination of Immunodominant Epitopes from Multispecific DNA-Based Vaccines Allows Induction of CD8 T Cells That Have a Striking Antiviral Potential. Journal of Immunology, 2009, 183, 370-380.	0.8	32
120	Peptide specific expansion of CD8+ T cells by recombinant plate bound MHC/peptide complexes. Journal of Immunological Methods, 2009, 340, 25-32.	1.4	3
121	The outermost Nâ€ŧerminal region of tapasin facilitates folding of major histocompatibility complex class I. European Journal of Immunology, 2009, 39, 2682-2694.	2.9	13
122	NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics, 2009, 61, 1-13.	2.4	725
123	Recombinant chymosin used for exact and complete removal of a prochymosin derived fusion tag releasing intact native target protein. Protein Science, 2009, 18, 1023-1032.	7.6	6
124	Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Research, 2009, 5, 2.	0.1	62
125	Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nature Immunology, 2009, 10, 636-646.	14.5	170
126	Immune hierarchy among HIVâ€1 CD8 <sup>+</sup> T cell epitopes delivered by dendritic cells depends on MHCâ€I binding irrespective of mode of loading and immunization in HLAâ€A*0201 mice. Apmis, 2009, 117, 849-855.	2.0	6

#	Article	IF	CITATIONS
127	In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine, 2009, 27, 6471-6479.	3.8	58
128	Oxidative stress can alter the antigenicity of immunodominant peptides. Journal of Leukocyte Biology, 2009, 87, 165-172.	3.3	33
129	The peptide-binding specificity of HLA-A*3001 demonstrates membership of the HLA-A3 supertype. Immunogenetics, 2008, 60, 633-643.	2.4	21
130	Structure of a SARS coronavirus-derived peptide bound to the human major histocompatibility complex class I molecule HLA-B*1501. Acta Crystallographica Section F: Structural Biology Communications, 2008, 64, 459-462.	0.7	15
131	Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS Journal, 2008, 275, 4097-4110.	4.7	30
132	A strategy for bacterial production of a soluble functional human neonatal Fc receptor. Journal of Immunological Methods, 2008, 331, 39-49.	1.4	28
133	Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Research, 2008, 36, W513-W518.	14.5	304
134	Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53. Proteome Science, 2008, 6, 18.	1.7	13
135	Identification of immunogenic HLA-B7 "Achilles' heel―epitopes within highly conserved regions of HIV. Vaccine, 2008, 26, 3059-3071.	3.8	42
136	HLA-A*0201-Restricted CD8+ Cytotoxic T Lymphocyte Epitopes Identified from Herpes Simplex Virus Glycoprotein D. Journal of Immunology, 2008, 180, 426-437.	0.8	84
137	Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan. PLoS Computational Biology, 2008, 4, e1000107.	3.2	254
138	NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. Nucleic Acids Research, 2008, 36, W509-W512.	14.5	722
139	One-Pot, Mix-and-Read Peptide-MHC Tetramers. PLoS ONE, 2008, 3, e1678.	2.5	103
140	Genetic Variation in AKAP13 Is Associated with Increased Risk of Relapse after Allogeneic Hematopoietic Cell Transplantation Following Non-Myeloablative Conditioning Blood, 2008, 112, 3257-3257.	1.4	0
141	CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine, 2007, 25, 2823-2831.	3.8	94
142	Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine, 2007, 25, 3179-3191.	3.8	65
143	Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors. Cancer Letters, 2007, 251, 86-95.	7.2	4
144	Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics, 2007, 8, 424.	2.6	687

#	Article	IF	CITATIONS
145	Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. Cancer Immunology, Immunotherapy, 2007, 56, 1755-1763.	4.2	22
146	NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence. PLoS ONE, 2007, 2, e796.	2.5	598
147	The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Letters, 2006, 231, 247-256.	7.2	50
148	Identification of MHC Class I H-2 Kb/Db-Restricted Immunogenic Peptides Derived from Retinal Proteins. , 2006, 47, 3939.		12
149	Crystal structures of two peptide–HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 1300-1310.	2.5	31
150	Structure of HLA-A*1101 in complex with a hepatitis B peptide homologue. Acta Crystallographica Section F: Structural Biology Communications, 2006, 62, 1179-1184.	0.7	5
151	Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nature Immunology, 2006, 7, 179-189.	14.5	91
152	Oriented coupling of major histocompatibility complex (MHC) to sensor surfaces using light assisted immobilisation technology. Biosensors and Bioelectronics, 2006, 21, 1553-1559.	10.1	21
153	A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I Molecules. PLoS Computational Biology, 2006, 2, e65.	3.2	254
154	A novel system for continuous protein refolding and on-line capture by expanded bed adsorption. Protein Science, 2005, 14, 2141-2153.	7.6	20
155	An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. European Journal of Immunology, 2005, 35, 2295-2303.	2.9	290
156	High-resolution structure of HLA-A*1101 in complex with SARS nucleocapsid peptide. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 1031-1040.	2.5	30
157	Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics, 2004, 20, 1388-1397.	4.1	254
158	Vaccination with p53-peptide?pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunology, Immunotherapy, 2004, 53, 633-641.	4.2	100
159	Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics, 2004, 55, 797-810.	2.4	269
160	Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA. Current Opinion in Immunology, 2004, 16, 137-142.	5.5	11
161	Changes in protein expression in p53 deleted spontaneous thymic lymphomas. Experimental Cell Research, 2004, 295, 91-101.	2.6	18
162	MHC Class I Epitope Binding Prediction Trained on Small Data Sets. Lecture Notes in Computer Science, 2004, , 217-225.	1.3	2

#	Article	IF	CITATIONS
163	Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC. Cellular Immunology, 2003, 222, 126-133.	3.0	25
164	Incomplete effector/memory differentiation of antigen-primed CD8+ T cells in gene gun DNA-vaccinated mice. European Journal of Immunology, 2003, 33, 1941-1948.	2.9	18
165	Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. European Journal of Immunology, 2003, 33, 3342-3352.	2.9	38
166	Clinical application of dendritic cells in cancer vaccination therapy. Apmis, 2003, 111, 818-834.	2.0	41
167	Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. Journal of Immune Based Therapies and Vaccines, 2003, 1, 1.	2.4	11
168	Comparison of CTL reactivity in the spleen and draining lymph nodes after immunization with peptides pulsed on dendritic cells or mixed with Freund's incomplete adjuvant. Immunology Letters, 2003, 90, 13-18.	2.5	7
169	Purification of correctly oxidized MHC class I heavy-chain molecules under denaturing conditions: A novel strategy exploiting disulfide assisted protein folding. Protein Science, 2003, 12, 551-559.	7.6	35
170	Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Science, 2003, 12, 1007-1017.	7.6	1,013
171	Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. Journal of General Virology, 2003, 84, 2409-2421.	2.9	40
172	Predicting proteasomal cleavage sites: a comparison of available methods. International Immunology, 2003, 15, 781-787.	4.0	86
173	Selecting Informative Data for Developing Peptide-MHC Binding Predictors Using a Query by Committee Approach. Neural Computation, 2003, 15, 2931-2942.	2.2	14
174	High-Throughput Polymerase Chain Reaction Cleanup in Microtiter Format. Analytical Biochemistry, 2001, 296, 149-151.	2.4	3
175	Phage display of peptide / major histocompatibility class I complexes. European Journal of Immunology, 2001, 31, 32-38.	2.9	22
176	Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. European Journal of Immunology, 2001, 31, 2986-2996.	2.9	46
177	Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. European Journal of Immunology, 2001, 31, 1239-1246.	2.9	41
178	Role of the T Cell Receptor Ligand Affinity in T Cell Activation by Bacterial Superantigens. Journal of Biological Chemistry, 2001, 276, 33452-33457.	3.4	58
179	Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. European Journal of Immunology, 2000, 30, 3089-3099.	2.9	47
180	Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. II. Cross-reaction between a monoclonal antibody and two alpha beta T cell receptors. Journal of Computer-Aided Molecular Design, 2000, 14, 71-82.	2.9	2

#	Article	IF	CITATIONS
181	Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. I. Recognition by two alpha beta T cell receptors. Journal of Computer-Aided Molecular Design, 2000, 14, 53-69.	2.9	13
182	Description and prediction of peptide-MHC binding: the â€ <sup>~</sup> human MHC project'. Current Opinion in Immunology, 1999, 11, 209-213.	5.5	67
183	Predicting Binding Affinities of Protein Ligands from Three-Dimensional Models:Â Application to Peptide Binding to Class I Major Histocompatibility Proteins. Journal of Medicinal Chemistry, 1999, 42, 4650-4658.	6.4	176
184	Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes. Vaccine, 1999, 18, 681-691.	3.8	34
185	Measurement of Peptideâ€MHC Interactions in Solution Using the Spin Column Filtration Assay. Current Protocols in Immunology, 1999, 31, Unit 18.4.	3.6	2
186	Complete Protection against Lethal <i>Toxoplasma gondii</i> Infection in Mice Immunized with a Plasmid Encoding the <i>SAG1</i> Gene. Infection and Immunity, 1999, 67, 6358-6363.	2.2	111
187	Binding of Peptides from the N-Terminal Region of α-Cliadin to the Celiac Disease-Associated HLA-DQ2 Molecule Assessed in Biochemical and T Cell Assays. Clinical Immunology and Immunopathology, 1996, 79, 288-293.	2.0	33
188	Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. European Journal of Immunology, 1996, 26, 1911-1918.	2.9	95
189	Biochemical analysis of peptide binding to MHC class I. , 1996, , 637-646.		0
190	Receptor-ligand interactions measured by an improved spun column chromatography technique A high efficiency and high throughput size separation method. Biochimica Et Biophysica Acta - General Subjects, 1995, 1243, 453-460.	2.4	51
191	A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules. European Journal of Immunology, 1994, 24, 385-392.	2.9	59
192	Preformed purified peptide/major histocompatibility class I complexes are potent stimulators of class I-restricted T cell hybridomas. European Journal of Immunology, 1994, 24, 1404-1409.	2.9	16
193	Structural requirements for the interaction between class II MHC molecules and peptide antigens. Immunologic Research, 1990, 9, 2-7.	2.9	13
194	Facts on the Fragmentation of Antigens in Presenting Cells, on the Association of Antigen Fragments with MHC Molecules in Cell-Free Systems, and Speculation on the Cell Biology of Antigen Processing. Immunological Reviews, 1988, 106, 181-193.	6.0	40
195	Structural Requirements of an Ovalbumin-Derived Immunogenic Peptide for T Cell Activation and Interaction with IAd. , 1988, , 178-185.		0
196	Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature, 1987, 328, 395-399.	27.8	382
197	The Interaction between Protein-Derived Immunogenic Peptides and Ia. Immunological Reviews, 1987, 98, 115-141.	6.0	215
198	Isolation and characterization of antigen-la complexes involved in T cell recognition. Cell, 1986, 47, 1071-1077.	28.9	471

#	Article	IF	CITATIONS
199	LARGE, BUT NOT SMALL, ANTIGENS REQUIRE TIMEâ€AND TEMPERATUREâ€DEPENDENT PROCESSING IN ACCESSORY CELLS BEFORE THEY CAN BE RECOGNIZED BY T CELLS. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section C, Immunology, 1986, 94C, 17-24.	0.2	2